Evidence map›Paper›PMID 41688849›Full record

ReviewEuropean journal of nuclear medicine and molecular imaging2026

Current and future perspectives of molecular breast imaging with [

Angela Collarino, Giusi Pisano, Carrie B Hruska, Giorgia Garganese, Amy M Fowler, Anita Florit, Gaiane M Rauch, Francesco Giammarile, Renato A Valdés Olmos, Daniela Di Giuda and 2 more

Abstract readReview
PubMed Publisher
In one paragraph

Review in European journal of nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Angela CollarinoNuclear Medicine Unit, Department of Diagnostic Imaging and Oncological Radiotherapy, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
Giusi PisanoNuclear Medicine Unit, Department of Diagnostic Imaging and Oncological Radiotherapy, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy. giusi.pisano@guest.policlinicogemelli.it.ORCID 0000-0001-9627-5065
Carrie B HruskaDepartment of Radiology, Mayo Clinic, Rochester, MN, USA.
Giorgia GarganeseUnità Operativa di Chirurgia degli Organi Genitali Esterni Femminili, Divisione di Ginecologia Oncologica, Dipartimento Scienze della Salute della Donna, del Bambino e di Sanità Pubblica, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
Amy M FowlerDepartment of Radiology, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.
Anita FloritNuclear Medicine Unit, Department of Diagnostic Imaging and Oncological Radiotherapy, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
Gaiane M RauchDepartment of Breast Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Francesco GiammarileNuclear Medicine and Diagnostic Imaging Section, Division of Human Health, Department of Nuclear Sciences and Applications, International Atomic Energy Agency (IAEA), Vienna, Austria.
Renato A Valdés OlmosInterventional Molecular Imaging Laboratory, Leiden University Medical Center, Leiden, The Netherlands.
Daniela Di GiudaNuclear Medicine Unit, Department of Diagnostic Imaging and Oncological Radiotherapy, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
Lenka M Pereira Arias-BoudaDepartment of Radiology, Section of Nuclear Medicine, Leiden University Medical Center, Leiden, The Netherlands.
Luigi MansiInteruniversity Research Center for Sustainability (CIRPS), Rome, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThis IAEA international expert panel aims to provide an updated overview of Molecular Breast Imaging (MBI) using [99mTc]Tc-sestamibi, emphasising its technical advances, current clinical applications in breast cancer and future perspectives.

methodsRelevant studies, clinical guidelines and technical reports were assessed to evaluate the use of MBI with [99mTc]Tc-sestamibi in breast cancer, focusing on evolving practices and technological advancements.

resultsMBI has evolved from its origins as scintimammography, benefiting from innovations such as dual-head cadmium zinc telluride detectors. Dedicated MBI systems offer higher sensitivity, improved spatial resolution and reduced radiation dose relative to conventional gamma cameras. MBI is a complementary tool to digital mammography, demonstrating ability to detect mammographically-occult breast cancer, especially in patients with dense breasts or inconclusive conventional imaging. Moreover, MBI-guided systems enable biopsy of the most metabolically active lesions.

conclusionMBI with [99mTc]Tc-sestamibi remains a valuable modality in breast imaging, offering high sensitivity for the detection of small, node negative disease and detection of large, advanced cancers that are undetected by mammographic screening. MBI is performed at a safe radiation dose, is well-tolerated by patients, and has exceedingly low risk of adverse events. Further efforts to reduce image acquisition time, assess cost-effectiveness and standardise protocols are essential to expand MBI’s clinical use.

Indexed as

Breast NeoplasmsMolecular ImagingTechnetium Tc 99m SestamibiFemaleHumansRadiopharmaceuticalsRadiopharmaceuticalsTechnetium Tc 99m Sestamibi[99mTc]Tc-sestamibiBreast cancerMBI-guided biopsyMolecular breast imaging

Identifiers

PMID41688849

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.